Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
gptkb:drug |
| gptkbp:ATCCode |
gptkb:N06BA01
|
| gptkbp:CASNumber |
60-13-9
|
| gptkbp:chemicalFormula |
C9H13N·HCl
|
| gptkbp:component |
gptkb:Adderall
gptkb:Evekeo |
| gptkbp:contains_active_ingredient |
amphetamine
|
| gptkbp:eliminationHalfLife |
9-14 hours
|
| gptkbp:excretion |
gptkb:kidney
|
| gptkbp:has_salt_form |
hydrochloride
|
| https://www.w3.org/2000/01/rdf-schema#label |
amphetamine hydrochloride
|
| gptkbp:is_a_stimulant |
yes
|
| gptkbp:IUPACName |
1-phenylpropan-2-amine hydrochloride
|
| gptkbp:legalStatus |
controlled substance
|
| gptkbp:listedOn |
gptkb:World_Health_Organization_Model_List_of_Essential_Medicines
|
| gptkbp:metabolism |
liver
|
| gptkbp:molecularWeight |
169.7 g/mol
|
| gptkbp:riskFactor |
abuse
dependence |
| gptkbp:routeOfAdministration |
oral
intravenous |
| gptkbp:sideEffect |
anxiety
loss of appetite insomnia increased blood pressure |
| gptkbp:usedFor |
gptkb:attention_deficit_hyperactivity_disorder
narcolepsy |
| gptkbp:bfsParent |
gptkb:Base_amphetamine
|
| gptkbp:bfsLayer |
6
|